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1. Introduction
Urinary tract infections (UTI) are among the most common bacterial infections in humans.
Approximately 50%-60% of adult women experience a UTI during their lifetime. Further‐
more, a significant number of patients can be characterized as having recurrent UTIs if they
meet the criteria of ≥2 uncomplicated UTIs in 6 months or ≥3 positive cultures within the
preceding 12 months. Applying this definition, it is estimated that recurrent UTIs affect 25%
of women with a history of UTI.
E. coli represents the main causative pathogen in recurrent UTI and is responsible for ap‐
proximately 80% of all episodes of infection. Further important pathogens include Proteus
mirabilis, Staphylococcus saprophyticus, and Klebsiella pneumonia.
Symptomatic UTIs cause significant discomfort such as dysuria, polyuria, and suprapubic
tenderness. If left untreated, a UTI can progress to acute pyelonephritis with the risk of per‐
manent renal scarring and loss of renal function.
Patients with recurrent urinary tract infections undergo frequent antibiotic treatment and/or
low-dose antibiotic prophylaxis. Additionally, a subset of patients is required to undergo a
systematic radiological and endoscopic evaluation of the urinary tract in order to rule out
any underlying structural abnormalities or urinary calculi. The immense use of antibiotics
for the treatment of urinary tract infections has resulted in the development of considerable
bacterial resistance and therefore, increasing difficulties in eradicating infections. Due to the
development of bacterial resistance, UTIs are a substantial economic burden and a notewor‐
thy public health issue. Therefore, new treatment strategies and preventive measures
against UTIs such as immune-stimulation/modulation, vaccine development, the use of pro‐
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biotics, and the instillation of attenuated bacteria into the urinary bladder are currently be‐
ing researched.
This chapter will review the most recent literature and provide up-to-date information on
developments in immune-based treatment strategies for patients with recurrent UTIs from a
pre-clinical and clinical point of view.
2. Material and methods
To identify all relevant materials, comprehensive literature searches were performed via the
data sources: MEDLINE, EMBASE, CINAHL and OVID using the key words: urinary tract
infection, urine culture, UTI, vaccines, adherence, fimbriae, biofilms, probiotics. Relevant ar‐
ticles and references between 1970 and 2012 were reviewed and analyzed. Reference lists
from relevant review articles were also searched. Only articles published as formal papers in
peer-reviewed journals were selected for inclusion if they reported findings of interest. The
data base searches resulted in 710 articles, of which 75 of 710 pertained directly to immune-
based treatment strategies. The entirety of these articles was reviewed, forming the basis for
the current review.
3. Results
Plant-derived therapies have long been used in Ayurvedic and traditional Chinese medicine
(Wollenweber, 1988). The interest in plant antimicrobials for treatment or prevention of
UTIs has been driven both by the prevalence of antibiotic-resistant uropathogens and grow‐
ing popularity of complementary and alternative medicine. Still, little evidence exists for the
effectiveness of these treatments and therapeutic dose requirements. More than 5000 plant
polyphenols have been identified so far. The spectrum of biological effects include anti-mi‐
crobiol, anti-inflammatory and anti-carcinogenic activities (Beretz et al., 1978). Plant derived
extracts contain different chemical compounds with multiple antimicrobial activities (Burt,
2004). The most studied species include cranberry, berberine, blueberry, bearberry, and cer‐
tain herbs such as cinnamon. According to Ohno et al., the potential for bacteria to develop
resistance to plant derived anti-microbials is relatively small (Ohno et al., 2003).
3.1. Cranberry
Cranberry, Vaccinium macrocapron, is the best known and most studied plant-derived ther‐
apy for UTIs (Seeram, 2008). Historically its antimicrobial effects were believed to be due in‐
creased excretion of hippuric acid and urinary acidification, although this was disproved in
the 1950’s (Bodel et al., 1959). More recent studies have proved Cranberry compounds fruc‐
tose and proanthocyanidin to inhibit E. Coli adhesins in vitro. This finding has given rise to
the currently held hypothesis that cranberry extracts prevent E. Coli adhesion to bladder
mucosa, thus decreasing the incidence of UTIs (Howell et al., 2005, Lavigne et al., 2008, Liu
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et al., 2006, Ofek et al., 1991, Ohnishi et al., 2006). More recently, other compounds such as
flavanoids, anthocyanins, catechin, triterpenoids, organic acids and ascorbic acid were iden‐
tified as constituents (Raz et al., 2004). A wide variety of cranberry products are employed
as treatment, the most common are cranberry juice concentrate, cranberry juice cocktail, and
capsules. In respect to prevention, randomised trials suggest that cranberry juice or cranber‐
ry-concentrate tablets reduce the risk of symptomatic recurrent infection by 12-20%, espe‐
cially in pre-menopausal women (Avorn et al., 1994, Kontiokari et al., 2001, Stothers, 2002).
The same results do not apply to men, elderly patients, or those requiring catheterization
(Jepson &Craig, 2008). When compared to the current standard of antibiotic treatment, tri‐
methoprim-sulfamethoxazole 480mg daily is more effective than cranberry capsules 500mg
twice daily to prevent recurrent UTIs over 12 months (Beerepoot et al.). High withdrawal
rates were common in these trials, as was the inability to confirm compliance with cranberry
prophylaxis. While some randomized clinical trials could not demonstrate that cranberry is
beneficial (Jepson et al., 2000), other clinical and epidemiological studies support the use of
cranberry in maintaining a healthy urinary tract (Perez-Lopez et al., 2009). Another pro‐
posed mode of action is the non-enzymatic generation of nitric oxide under acidic condi‐
tions(MacMicking et al., 1997). Nitric oxide has significant anti-microbial activity. Up until
now, no evidence exists that cranberry extracts are effective to treat UTIs, while some data
support its use as prophylactic agent in the prevention of UTIs (Guay, 2009).
3.1.1. Berberine
Berberine sulfate is an alkaloid found in the Berberine arisata plant, as well as the roots of
Oregon Grape (Mahonia aquifolium), Goldenseal (hydrastis canadensis), and Goldenthread
(Coptis chinesis). It is present in the root, rhizome, and stem bark of the plants (Yarnell,
2002). Head et al. could show that berberine extracts are effective against a variety of organ‐
isms, including bacteria, viruses, fungi, and protozoans (Head, 2008). Growth inhibitory ef‐
fects were described for several bacterial pathogens such as Staphylococcus aureus,
Pseudomonas aeruginosa,, E. coli, Bacillus subtilis and Chlamydia (Cernakova &Kostalova,
2002, Head, 2008, Scazzocchio et al., 2001). In one study berberine was found to decrease
synthesis and expression of E. Coli Pap fimbriae, thus decreasing bacterial adhesion to epi‐
thelia in vitro (Sun et al., 1988). Similarly, berberine sulfate was found to prevent Streptococ‐
cus pyogenes to adhere to host cells (Sun et al., 1988). Another potentially important mode
of action, is the alteration of the bacterial cell division through targeting the FtsZ protein
(Domadia et al., 2008). However, the mechanisms behind the anti-microbial properties of
berbine are not well studied. Although berberine has been included in Chinese urinary med‐
ications for centuries, no in vivo studies or clinical trials have been published to evaluate its
effectiveness.
3.1.2. Blueberry
Blueberry, part of the Vaccinium genus, is closely related to cranberry. Studies suggest that
high molecular weight pranthocyanidins found in wild blueberry inhibit E. Coli adhesion in
vitro (Head, 2008, Ofek et al., 1996, Ofek et al., 1991). It was also shown, that the constituents
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in blueberry extracts similarly to those in cranberry extracts inhibit uropathogenic E. coli
(UPEC) from adhering to the uroepithelial cells using the mannose-resistant adhesin. This
was measured by the ability of prepared blueberry fractions to suppress the agglutination of
human red blood cells after incubation with UPEC strains (Schmidt et al., 2004). No relevant
trials of blueberry alone for UTI prevention or treatment were found at this time.
3.1.3. Bearberry
Bearberry, Arcystaphylos uva-ursi, is a member of the Ericaceae family, as are cranberry and
blueberry. The glycoside arbutin is the main constituent of bearberry leaves and dried prep‐
aration. Arbutin is metabolized into hydroquinone, which has a urinary availability of ap‐
proximately 65% of the administered arbutin dose (Schindler et al., 2002). Hydroquinone is
an antimicrobial according to in vitro studies, although there are no in vivo studies to prove
its effectiveness (Frohne, 1970). Turi et al. showed that growth of clinical isolates of UPEC in
the presence of Arcystaphylos uva-ursi extracts change microbial cell surface characteristics
by increasing the microbial cell surface hydrophobicity, thereby decreasing their ability to
adhere to host cells (Turi et al., 1997). Furthermore, Arcystaphylos uva-ursi was described as
diuretic and anti-inflammatory agent, effects that are supportive in the treatment of UTIs
(Beaux et al., 1999, Kubo et al., 1990).
Currently, bearberry is used in Germany to cure mild UTI, defined as asymptomatic or bac‐
teriuria less than 105 colony-forming units/mL (Schindler et al., 2002). It is not, however, rec‐
ommended for long-term prevention due to concern of hydroquinone carcinogenic effects
(DeCaprio, 1999).
3.1.4. Trans-cinnamaldehyde
Trans-cinnamaldehyde is an extract of the bark of cinnamon (Adams et al., 2004). It has a
wide margin of safety between conservative estimates of intake and no observed adverse ef‐
fects (Adams et al., 2004). In vitro studies demonstrated antibacterial activity against Clostri‐
dium botulinum, S. aureus, E. coli O157:H7 and Salmonella Typhimurium. Recently, it was
shown that trans-cinnamaldehyde has the ability to inhibit UPEC biofilm formation on uri‐
nary catheters and to inhibited the adhesion and invasion of uroepithelial cells by UPEC by
down regulation of major virulence genes (Amalaradjou et al.). Other antimicrobial mecha‐
nisms include changes in the permeability of cell membranes, inhibitory effects on enzymes
such as amino acid decarboxylases and inhibiting the production of virulence factors (Gill
&Holley, 2006, Sikkema et al., 1994, Smith-Palmer et al., 2002).
These results justify further pre-clinical studies and make trans-cinnamaldehyde a potential
candidate for use as an antimicrobial agent for controlling UTIs.
3.1.5. Others
The existing literature lists many other herbs for the treatment of UTIs, while most of them
lack a scientific basis for this purpose. They include Taraxacum officinalis leaf (dandelion),
Juniperus communis (juniper), Hydrangea aborescens (hydrangea), Agrimonia eupatoria
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(agrimony), Elymus repens (couchgrass), Althea officinalis (marshmallow), Zea mays (corn
silk), Apium graveolens (celery seed), Ulmus fulva (slippery elm), Arctium lappa (burdock),
and Mentha piperita (peppermint). For others some scientific background exists. Extracts
from Salvia officinalis (Garden sage or common sage) has been shown to be active against
Klebsiella, Enterobacter species, UPEC, Proteus mirabilis and Morganella morganii obtained
from the urine samples from patients with UTIs (Pereira et al., 2004).
Another potentially useful herb is Barosma betulina (bachu). It has been used in the treat‐
ment of UTI and urethritis for a long time. It was found to have anti-microbial effects
against uropathogens in vitro and diuretic properties (Simpson, 1998).
3.2. Vaginal probiotics/lactobacilli
Studies could demonstrate that Lactobacilllus species in the form of probiotics reduced the
risk of UTIs and vaginal infections (Bruce &Reid, 2003, Reid et al.,1985). However, despite
ongoing research the mechanisms are poorly understood (Spiegel et al., 1980). In the litera‐
ture were different mode of action proposed including downregulation of pro-inflammatory
cytokines (IL-6, IL-8, TNF-alpha) (Anukam et al., 2009), production of hydrogen peroxide,
which protects against the UPEC (Czaja et al., 2007) production of a 29-kDa biosurfactant
proteins which inhibits bacterial adhesion (Osset et al., 2001, Xia et al., 2006). Some of the
commensal bacteria such as Lactobacillus species and Bifidobacteria species are known to
produce immunoregulatory factors that modulate the immune response and may therefore
decrease UTIs (Wilson et al., 1998). From a clinical standpoint, there is a close correlation be‐
tween loss of the normal genital microbiota, particularly Lactobacillus species, and an in‐
creased incidence of genital and bladder infections. Vaginal colonization with Lactobacillus
spp. was found to prevent recurrent UTIs (Bruce &Reid, 1988, Reid et al., 1992). A Phase I
clinical trial assessed the safety of the use of vaginal Lactobacillus suppositories to prevent
recurrent (Czaja et al., 2007). Reid et al. investigated in a randomized study the role of probi‐
otic lactobacilli in controlling re-infection in women after treatment of an acute UTI (Reid et
al., 1992). 235 patients were treated with antibiotics for three days. Recurrence occurred in
41% of the patients. Individuals with recurrence were randomly assigned to Lactobacillus
suppositories treatment group or placebo suppository group. Treatment was given twice
weekly for two weeks, then once a month for the next two months. The recurrence rate was
21% in the Lactobacillus group compared to 47% in the placebo group. Oral use of Lactoba‐
cilli was also investigated. Reid et al. demonstrated L. rhamonosus GR-1 and L. fermentum
RC-14 taken orally lead to colonization of vaginal epithelium within one week. In pediatric
patients the oral intake of L. rhamnosus GG resulted in a reduction in UTI incidence rate
compared to the placebo group (Dani et al., 2002). These results are promising and warrant
further pre-clinical and clinical studies for the use of probiotics in controlling UTIs.
3.3. Immuno-stimulation/vaccines
Currently, low-dose antibiotic treatment has been the most effective prophylaxis for the pre‐
vention of recurrent UTI. However, cessation of antibiotic treatment usually results in recur‐
rence of infection in most patients (Ha &Cho, 2008). Furthermore, with the number of
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antibiotic resistant strains of uropathogenic bacteria causing recurrent UTI on the rise, a sub‐
stantial amount of research in alternative treatment modalities such as immuno-stimulation
and attenuated vaccines is being performed. The target of such modalities consists of the
Mucosa-Associated Lymphoid Tissue (MALT) lining much of the GI, respiratory, and geni‐
tourinary tract, the activation of specific receptors on dendritic cells within the genitourina‐
ry tract, and increasing the concentration bacteria-specific immunoglobulins (Ha &Cho,
2008). The objective of such therapies is to reduce the frequency and severity of UTI as well
as reduce the consumption of antibiotics used to treat them.
Uro-Vaxom® (OM-89) is an extract of 18 strains of E. coli that is obtained by alkaline lysis,
which destroys lipopolysaccharide (LPS) molecules produced by the gram negative bacteria
and modifies other bacterial antigens, maintaining their antigenic potential (Ha &Cho,
2008). Taken orally, Uro-Vaxom® achieves immuno-stimulation by increasing the prolifera‐
tion of Mucosal Associated Lymphoid Tissue (MALT) within the GI tract leading to elevated
concentrations of bacteria-specific IgG, mucosal-derived IgA along with serum IgA. Further‐
more, OM-89 increases the rate of dendritic cell maturation within the genitourinary tract,
leading to increased numbers of circulating memory T-cells as well as an overall increase in
inflammatory mediators such as TNF-alpha, IL-2, and IL-6 (Bessler et al., 2009). Treatment
studies of sexually active females between the age of 20 and 50 shows that Uro-Vaxom® re‐
duces the recurrence of UTI by 36% after 6 months of therapy compared to placebo (Bessler
et al., 2009).
Solco Urovac, which is currently under phase 2 clinical trials, is a treatment modality that
utilizes the vaginal mucosa via suppository to induce an immune response. The Solco Uro‐
vac vaccine consists of 6 E. coli strains along with several recombinant antigenic factors such
as fimbriae proteins and 1 strain each of Proteus mirabilis, Morganella morganii, Klebsiella
pneumonia, and Enterococcus faecalis (Hopkins et al., 2007). SolcoUrovac works in a similar
manner to that of OM-89, however it achieves a higher overall mucosal concentration of IgA
in the vagina and bladder. One characteristic of SolcoUrovac is that it must be administered
on a booster schedule or else the maximum efficacy will not be achieved. The overall reduc‐
tion of UTIs in female patients between the age of late teens to early 70s treated with Sol‐
coUrovac plus multiple boosters was measured to be 46.0% (Hopkins et al., 2007).
Siderophores, such as the IroN-cell surface protein found on most strains of E. Coli, are poten‐
tial targets for immune-therapy. A significant systemic-compartment IroN IgG-specific anti‐
body response  developed in  serum.  However,  there  was  no IroN IgA-specific  antibody
response in either the systemic or the mucosal compartment. Subcutaneous immunization
with denatured IroN resulted in a significant IroN immunoglobulin G (IgG)-specific response
in serum but not a systemic or mucosal IroN-specific IgA response (Russo et al., 2003).
3.4. Inhibition of bacterial adhesion
UPEC strains express a number of virulence factors used for colonization of their host. One
important virulence factor is located on type 1 pili, allowing UPEC to adhere and invade
host cells within the urinary tract. FimH interactions with several host factors have been
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documented. These include components of the glycocalyx that sparsely covers the bladder
surface, carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family mem‐
bers, soluble Tamm-Horsfall protein, the glycosylphosphatidylinositol (GPI)-anchored pro‐
tein CD48, the leukocyte adhesion molecules CD11 and CD18, and uroplakin 1a (Klein et
al.). Adherence to mannose residues prevents the rapid clearance of E. coli from the urinary
tract by the flow of urine and enables the invasion of the host cells (Wellens et al., 2008). The
binding of type one pili to bladder epithelial cells activates the innate immune system via
the Toll-like receptor 4 pathway which recruits neutrophils and other inflammatory media‐
tors to the site of insult (Wellens et al., 2008). Next, the complement system opsonizes the
UPEC and counter intuitively facilitates invasion of the bacteria into the epithelial cell.
Type 1 pili are the most prevalent fimbriae encoded by UPEC, consisting of the four subu‐
nits FimA, FimF, FimG, and FimH, the latter located at the tip of the pili (Wellens et al.,
2008). The FimH moiety, which is the primarily subunit responsible for the initiation of bac‐
terial adherence and invasion, is a prime target of immune-stimulation. Experiments done in
mice have shown that both direct inoculation with immunogloblins against FimH, innocula‐
tion with synthetic peptides within the binding moiety for FimH, or gene knock-out of
FimH could specifically block type 1 fimbriae-mediated bacterial adherence to bladder epi‐
thelial cells resulting in a dramatic loss of virulence(Thankavel et al., 1997). In experiments
that utilized synthetic peptides to induce an immune response, dramatic increases in serum
IgG and IgM were observed via ELISA (Thankavel et al., 1997). In addition, urine collections
showed a marked increase in IgG and mucosal derived IgA along with elevated activity of
mast cells within the bladder epithelium when faced with a bacterial challenge (Thankavel
et al., 1997).
3.5. Inhibition of bacterial biofilms
Catheter–associated urinary tract infections are common and often related to the existence of
bacterial bio-films. Progress in this area is limited. Preventive strategies include avoiding
unnecessary catheterization, limit duration of catheterization, using closed drainage system,
and appropriate hygiene, including frequent catheter changes and emptying of the drainage
bags (Jacobsen et al., 2008, Newman, 1998). Many mechanisms of biofilm resistance against
antibiotic treatment were reported over the years. The most important type of the biofilm
resistance is the development of a diffusion barrier formed by the bio-film matrix (Ishida et
al., 1998). The biofilm prevents access of antimicrobial agents and even of antibodies. De‐
spite the antibiotic treatment, the infection often persists until the device is removed (Schier‐
holz &Beuth, 2001). Over the last 2 decades different coatings were explored to reduce the
risk of bacterial bio-film formation and bacterial colonization and subsequently infection.
Coating substances included various antibiotics, silvercoating and others. Infections could
not be prevented, however the “abacterial window” could be prolonged. Schaeffer et al.
demonstrated that in patients with acute spinal cord injury, who received long-term urinary
catheters, the silver-coated catheters delayed but did not prevent the onset of bacteriuria
(Schaeffer et al., 1988). The same findings were reported for antibiotic impregnation of cath‐
eters (Darouiche et al., 1999, Guay, 2001, Johnson et al., 1999). These findings are important
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for short-term use of urinary catheters but not for long-term use (Trautner &Darouiche,
2004). Several other substances were reported to inhibit development of bacterial bio-film
formation including type A proanthocyanidins, hesperidin, apigenin,naringin and rhoifoli‐
na, and others. None of these substances made it into clinical trials so far.
3.6. Stimulation of cyclic adenosine/forskolin
One important survival mechanism of UPEC is the creation of an intracellular reservoir.
Within the epithelial cell, the UPEC are able to resist antibiotic treatment by binding to Rab
27 b/CD 63 positive vesicles. Forskolin, the active component of the Coleus forskohlii, has
been proven to increase the content of cyclical adenosine monophosphate (cAMP) in urothe‐
lial cells, leading uropathogenic bacteria to exit the urothelial cells. It was shown that cAMP
levels regulate the exocytosis of these vesicles depending on the bladder distension. These
findings could lead to new approaches for the treatment and prevention of recurrent urinary
tract infections (Bishop et al., 2007, Gonzalez-Chamorro et al.).
3.7. Hormone therapy
Hormonal deficiency in postmenopausal women results in thinning of the vaginal and ure‐
thral mucosa and more importantly to disruption of the normal vaginal flora and therefore
to an increased risk for UTIs (Head, 2008). Several studies could demonstrate, that replacing
estrogene in this patient population can reduce the incidence of UTIs.
In a randomized study postmenopausal women received either intra-vaginally administered
estradiol or placebo. At the end of the study a significant reduction in the incidence of UTIs
in the treatment group compared to the placebo group was noted. Of interest is also the ob‐
servation that Lactobacilli that were absent in the vaginal cultures of patients of the treat‐
ment group at the beginning of the trial reappeared in 61% (Raz &Stamm, 1993).
3.8. Instillation of attenuated bacteria into the urinary bladder
Darouiche et al. conducted a prospective, randomized, placebo-controlled, double-blind pi‐
lot trial to examine the efficacy of bacterial interference in preventing urinary tract infection
(Darouiche et al., 2005). In this study 27 patients with spinal cord injury were included. Pa‐
tients were randomly assigned either to have their bladders inoculated with either E. coli
83972 (experimental group) or sterile normal saline (control group). Patients whose bladders
became colonized with E. coli 83972 were half as likely (P=.01) than non-colonized patients
to develop UTI during the subsequent year.
Billips et al. demonstrated recently that deletion of the O antigen ligase gene, waaL, from the
uropathogenic E. coli isolate NU14 results in a strain that stimulates enhanced urothelial cy‐
tokine secretion (Billips et al., 2009). They could show that NU14 DwaaL stimulated an en‐
hanced interleukin-6 secretion by mouse macrophages, compared with secretion by the wild
type. Of great importance is the fact that mice vaccinated via instillation into the bladder de‐
veloped protective responses that prevented persistent colonization after bladder challenge
with NU14, yet NU14 DwaaL failed to persistently colonize the mouse bladder. They could
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also show that the mice were additionally protected against challenge with a broad range of
clinical UPEC isolates and developed immunity that lasted more than 8 weeks (Billips et al.,
2009). These findings open a new avenue for future treatment strategies of recurrent urinary
tract infection by caused by UPEC.
4. Discussion
Immune-based treatment strategies for patients with recurrent UTIs are of special interest.
Several promising new approaches including bladder colonization with attenuated bacteria
and intravesical vaccination were published recently and discussed in this chapter. Further‐
more, studies suggest that the use of inhibitors of bacterial adherence to urothelial cell and
inhibitors of biofilm formation receptors hold great promise. Moreover, stimulators of cyclic
AMP inside urothelial cells and the recent advancements in the development of vaccines are
an interesting initiative in this field. For some of the plant –based prevention and treatment
strategies only little scientific evidence for the prevention and treatment of urinary tract in‐
fection exist.
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